GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong Finance21:18 ET

Is the breakthrough path all in AI? Chain pharmacies are facing a wave of closures and an era of low profits.

① In 2024, particularly in the second half of the year, chain pharmacies will face a large-scale wave of closures, and leading chain pharmacies will generally enter a low-profit era. ② AI is also being assigned higher expectations in helping pharmacies reduce costs and increase efficiency. ③ Publicly available large models, due to a lack of support from vertical domain data, are still insufficient to support the actual Business Operation of pharmacies.

cls.cnMar 16 02:09 ET

Livzon Pharmaceutical Group Inc. (SZSE:000513) Looks Inexpensive But Perhaps Not Attractive Enough

Simply Wall StMar 15 21:57 ET

AI and policy are driving forces! Hong Kong pharmaceutical stocks collectively "rebound" with WUXI BIO surging over 14% to lead the Industry.

① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?

cls.cnMar 14 00:35 ET

Hong Kong stocks are experiencing fluctuations | CRO Concept stocks are warming up. The integration of AI and CXO has entered a new stage. Institutions claim that the external environment for CRO may be improving.

As of the time of writing, the CRO Concept has warmed up, with VIVA BIOTECH (01873) rising by 11.89% to 1.6 HKD; WUXI BIO (02269) increasing by 10.3% to 25.7 HKD; PHARMARON (03759) up by 5.67% to 16.04 HKD; and TIGERMED (03347) climbing by 5.86% to 37.05 HKD.

Zhitong FinanceMar 13 22:47 ET

LIVZON PHARMA (01513.HK) plans to hold a Board of Directors meeting on March 26 to approve the annual performance.

Gelonghui reported on March 12 that LIVZON PHARMA (01513.HK) announced that the Board of Directors has scheduled a board meeting on Wednesday, March 26, 2025, to review and approve the annual results of the company and its subsidiaries for the year ending on March 12, 2025, consider the proposal for the final dividend distribution (if applicable), and address other matters (if any).

Gelonghui FinanceMar 12 04:42 ET